Economic Impact of Venous Thromboembolism After Hip and Knee Arthroplasty

Potential Impact of Rivaroxaban

Richard J Friedman; Nishan Sengupta; Michael Lees


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(3):299-306. 

In This Article

Compliance with Anti-thrombotic Guidelines

Despite the guidelines, many patients do not receive effective prophylaxis;[21] one study found that fewer than one in five elderly patients received post-discharge thromboprophylaxis after THA or TKA.[22] Analysis of the Global Orthopaedic Registry (GLORY) found that whereas almost all THA patients received a form of prophylaxis, only 47% of patients received prophylaxis in compliance with ACCP guidelines in terms of type, duration, start time and dose.[23] There are a number of possible reasons for this lack of adherence, including concerns about the risks of prophylaxis.[24–26] However, there is little evidence that prophylaxis causes surgical bleeding or that bleeding after arthroplasty compromises the short- or long-term outcomes.[27] In fact, the rate of major bleeding after major knee surgery was found to be similar in patients who received LMWH or placebo (2.5 vs 2.4%).[28] Another potential barrier to the optimal use of thromboprophylaxis could be the inconvenience of sc. administration or coagulation monitoring[29] and overall costs associated with currently available agents,[30,31] particularly in light of recommendations for extended post-discharge thromboprophylaxis. The ideal regimen for an anticoagulant for optimal convenience would be once-daily (q.d.) oral provision,[30] which may also facilitate compliance.[32]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.